✦ LIBER ✦

Oral cyclophosphamide for refractory or relapsing thrombotic thrombocytopenic purpura (TTP)

✍ Scribed by HERTZBERG, M. S. ;KOUTTS, J.

Book ID: 108999804
Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 105 KB
Volume: 27
Category: Article
ISSN: 0004-8291
DOI: 10.1111/j.1445-5994.1997.tb02204.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab for treatment of refractory/re

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)

✍ Afaq Ahmad; Anita Aggarwal; Daya Sharma; Harish P. Dave; Virginia Kinsella; Marg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Abstract Plasma exchange is the standard treatment for thrombotic thrombocytopenic purpura (TTP). For patients refractory to plasma exchange, treatment options are limited and often unsuccessful. The platelet thrombi that form in acquired TTP are believed to result from the presence of procoagul

Cyclophosphamide for chronic relapsing t

Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura

✍ Bird, JenniferM.; Cummins, David; Machin, SamuelJ. 📂 Article 📅 1990 🏛 The Lancet 🌐 English ⚖ 389 KB

Cyclophosphamide for chronic relapsing t

Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura

✍ Udvardy, Miklos; Rak, Kalman 📂 Article 📅 1990 🏛 The Lancet 🌐 English ⚖ 349 KB

Rituximab maintenance for relapsed refra

Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura

✍ Vinai C. Bhagirath; John G. Kelton; Jane Moore; Donald M. Arnold 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 301 KB

Role of splenectomy in patients with ref

Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura

✍ Nicole A. Aqui; Steven H. Stein; Barbara A. Konkle; Charles S. Abrams; Frank J. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

## Abstract Thrombotic thrombocytopenic purpura (TTP) was once uniformly fatal. Therapeutic plasma exchange in combination with immunosuppressive and anti‐platelet agents, however, have resulted in improved survival rates of greater than 80% for patients with TTP. In spite of aggressive plasma exch

Rituximab for the treatment of refractor

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases

✍ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp